USA - NASDAQ:CTKB - US23285D1090 - Common Stock
The current stock price of CTKB is 4.065 USD. In the past month the price increased by 21.04%. In the past year, price decreased by -17.81%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 24.92 | 210.76B | ||
| DHR | DANAHER CORP | 27.65 | 152.65B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 143.51 | 46.81B | ||
| A | AGILENT TECHNOLOGIES INC | 26.28 | 40.60B | ||
| IQV | IQVIA HOLDINGS INC | 18.78 | 37.13B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 34.09 | 28.72B | ||
| WAT | WATERS CORP | 28.05 | 20.42B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 40.28 | 20.48B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.05 | 16.49B | ||
| TEM | TEMPUS AI INC | N/A | 15.48B | ||
| ILMN | ILLUMINA INC | 22.9 | 14.64B | ||
| ICLR | ICON PLC | 12.57 | 12.90B |
Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 688 full-time employees. The company went IPO on 2021-07-23. The firm is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.
CYTEK BIOSCIENCES INC
47215 Lakeview Boulevard
Fremont CALIFORNIA US
Employees: 688
Phone: 18779229835
Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 688 full-time employees. The company went IPO on 2021-07-23. The firm is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.
The current stock price of CTKB is 4.065 USD. The price decreased by -3.21% in the last trading session.
CTKB does not pay a dividend.
CTKB has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
CYTEK BIOSCIENCES INC (CTKB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.05).
CYTEK BIOSCIENCES INC (CTKB) currently has 688 employees.
The outstanding short interest for CYTEK BIOSCIENCES INC (CTKB) is 5.44% of its float.
ChartMill assigns a technical rating of 7 / 10 to CTKB. When comparing the yearly performance of all stocks, CTKB is a bad performer in the overall market: 71.57% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to CTKB. While CTKB has a great health rating, there are worries on its profitability.
Over the last trailing twelve months CTKB reported a non-GAAP Earnings per Share(EPS) of -0.05. The EPS increased by 45.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.3% | ||
| ROE | -1.7% | ||
| Debt/Equity | 0 |
11 analysts have analysed CTKB and the average price target is 5.23 USD. This implies a price increase of 28.6% is expected in the next year compared to the current price of 4.065.
For the next year, analysts expect an EPS growth of -308% and a revenue growth -3.3% for CTKB